TMSB10 and benign prostatic hyperplasia: Immunohistochemical analysis confirmed these findings (Fig. 4), showing a progressive increase in TMSB10 expression from BPH to localized and metastatic high-grade prostate cancer, with significantly higher levels in metastatic cases (P < 0.0001).